{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moniliasis%2C+Vulvovaginal", "query": { "condition": "Moniliasis, Vulvovaginal" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moniliasis%2C+Vulvovaginal&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T13:15:28.842Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05399641", "title": "Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vulvovaginal Candidiasis" ], "interventions": [ { "name": "Ibrexafungerp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2022-05-01", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 25, "location_summary": "Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05399641" }, { "nct_id": "NCT03734991", "title": "Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candida Vulvovaginitis" ], "interventions": [ { "name": "Ibrexafungerp", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "FEMALE", "summary": "12 Years and older · Female only" }, "enrollment_count": 376, "start_date": "2019-01-04", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2021-09-08", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734991" }, { "nct_id": "NCT01039584", "title": "A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vulvovaginal Candidiasis" ], "interventions": [ { "name": "Butoconazole Nitrate Vaginal Cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gynazole 1 vaginal cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Padagis LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 611, "start_date": "2008-02", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01039584" }, { "nct_id": "NCT01812889", "title": "Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vaginal Infection" ], "interventions": [ { "name": "TOL-463 Vaginal ovule", "type": "DRUG" }, { "name": "TOL-463 Vaginal gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 26, "start_date": "2013-04", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-16", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01812889" }, { "nct_id": "NCT03987620", "title": "Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candida Vulvovaginitis" ], "interventions": [ { "name": "Ibrexafungerp", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "FEMALE", "summary": "12 Years and older · Female only" }, "enrollment_count": 455, "start_date": "2019-06-07", "completion_date": "2020-04-29", "has_results": true, "last_update_posted_date": "2021-09-08", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 21, "location_summary": "Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hialeah", "state": "Florida" }, { "city": "North Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03987620" }, { "nct_id": "NCT02971007", "title": "Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vulvovaginitis", "Yeast Infection", "Yeast Infection Vaginal", "Candidiasis, Vulvovaginal" ], "interventions": [ { "name": "Oral Encochleated Amphotericin B (CAMB)", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matinas BioPharma Nanotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 137, "start_date": "2016-11", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02971007" }, { "nct_id": "NCT06438575", "title": "Point of Care Diagnosis of Vaginal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vaginitis", "Bacterial Vaginosis", "Yeast Vaginitis", "Trichomonas Vaginitis" ], "interventions": [ { "name": "Xpert® Xpress MVP test", "type": "DIAGNOSTIC_TEST" }, { "name": "Usual Care", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Sharon L Hillier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "FEMALE", "summary": "14 Years and older · Female only" }, "enrollment_count": 351, "start_date": "2024-06-16", "completion_date": "2025-03-26", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06438575" }, { "nct_id": "NCT03059992", "title": "Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Invasive Candidiasis", "Mucocutaneous Candidiasis", "Coccidioidomycosis", "Histoplasmosis", "Blastomycosis", "Chronic Pulmonary Aspergillosis", "Allergic Bronchopulmonary Aspergillosis", "Invasive Pulmonary Aspergillosis", "Recurrent Vulvovaginal Candidiasis", "Other Emerging Fungi" ], "interventions": [ { "name": "Ibrexafungerp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2017-04-01", "completion_date": "2023-08-25", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059992" }, { "nct_id": "NCT03253094", "title": "Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Candida Vulvovaginitis" ], "interventions": [ { "name": "Fluconazole", "type": "DRUG" }, { "name": "SCY-078", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 186, "start_date": "2017-08-01", "completion_date": "2018-05-04", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03253094" }, { "nct_id": "NCT02888197", "title": "Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Candidiasis, Vulvovaginal", "Yeast Infection", "Mycoses", "Moniliasis, Vulvovaginal", "Vaginitis, Monilial" ], "interventions": [], "intervention_types": [], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2016-08-16", "completion_date": "2017-03-15", "has_results": false, "last_update_posted_date": "2018-03-02", "last_synced_at": "2026-07-23T13:15:28.842Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02888197" } ] }